News Roche cancer guru quits to lead 'off-the-shelf' T-cell R&D a... San Francisco biotech developing therapy for post-transplant blood disorder
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News BMS strikes three-year cancer R&D deal with Flatiron Bristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and patient-focused.
News J&J could pay $1 billion for oncolytic virus firm BeneVir J&J follows Merck & Co, and BMS with oncolytic virus acquisition
News Novartis matches Gilead on price in new CAR-T use Novartis won't offer 'money back' scheme because of delayed effect
News Ipsen takes on BMS as kidney cancer pill launches in EU Cabometyx could take market share from Opdivo
News Curium strikes $8bn deal to buy radiopharma rival Lantheus Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
